

Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Synthesis and Characterization of Bisoxazolines- and Pybox-Copper(II) Complexes and Their Application in the Coupling of α -Carbonyls with Functionalized Amines

Cite this: DOI: 10.1039/x0xx00000x

Received 00th January 2012,
Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Wei-Guo Jia,^{a*} Dan-Dan Li,^a Yuan-Chen Dai,^a Hui Zhang,^a Li-Qin Yan,^a En-Hong Sheng,^{a*} Yun Wei,^a Xiao-Long Mu,^a Kuo-Wei Huang^{b*}

Binuclear complexes $[(\text{DMOX})\text{CuCl}]_2(\mu\text{-Cl})_2$ (**1**), mononuclear $[(\text{DMOX})\text{CuBr}_2]$ (**2**) (DMOX = 4,5-Dihydro-2-(4,5-dihydro-4,4-dimethyloxazol-2-yl)-4,4-dimethyloxazole) and Pybox Cu(II) complex $[(\text{Dm-Pybox})\text{CuBr}_2]$ (**3**) (Dm-Pybox = 2,6-bis[4',4'-dimethyloxazolin-2'-yl]pyridine) were obtained by the reactions of CuX_2 (X = Cl, Br) with DMOX and Dm-Pybox ligand, respectively. The molecular structures of **1**, **2** and **3** have been determined by single-crystal X-ray diffraction analyses. The complexes **2** and **3** are efficient in catalyzing α -amination of ketones and esters through α -bromo carbonyl intermediate. The procedures are environmentally benign methods using molecular oxygen as oxidant with water as the only byproduct.

Introduction

Bisoxazolines¹ and tridentate *NNN* Pybox pincer ligands² are important ligands in organometallic chemistry with broad application in homogeneous catalysis and asymmetric synthesis. Typically, these ligands are good σ -donors, weak π -acceptors and can be easily modified to attain the desired steric, bulkiness- or electronic properties. Furthermore chirality can be endowed by using appropriate commercially available amino alcohol precursor. Within the past two decades, reports about bisoxazolines and Pybox transition metal complexes' exceptional catalytic abilities have been published.³ Coupling our continued interests in Cu complexes due to their superior catalytic activities,⁴ we seek to discover new Cu complexes to exploit their chemistry in a variety of potential catalytic applications.⁵

Aromatic unit attached at the α -position of a ketone, ester or amide represent an important structural motif in nature products, pharmaceuticals and organic synthetic intermediates.⁶ Thus efforts have not be spared to construct tailored amine substrates at the carbonyl α -position. Recently, Loh and coworkers first discovered a useful α -amination of carbonyl compounds reactions;⁷ Miura and coworkers described the synthesis of α -amino acid derivatives and ester using copper catalysts;⁸ MacMillan and co-workers published a procedure for the preparation of α -amination of ketones, esters, and aldehyde *via* copper catalysis and bidentate nitrogen ligands have shown excellent results.⁹ More importantly, these

procedures are environmentally benign methods due to the advantages of catalysts regeneration and using molecular oxygen as oxidant with water as the byproduct.

In this work, we report the synthesis and characterization of three novel Cu(II) complexes with bisoxazolines and tridentate pybox pincer ligands: $[(\text{DMOX})\text{CuCl}]_2(\mu\text{-Cl})_2$ (**1**), $[(\text{DMOX})\text{CuBr}_2]$ (**2**) and $[(\text{Dm-Pybox})\text{CuBr}_2]$ (**3**), and further examine their catalytic ability in the direct α -amination of ketones and esters. Our preliminary results suggests that Cu complexes **3** show promising catalytic activity in direct α -amination of ketones and esters with a broad substrate scope. Solid state structures of the Cu complexes **1**, **2** and **3** were also revealed with single crystal X-ray diffraction studies.

Results and discussion

Binuclear $[(\text{DMOX})\text{CuCl}]_2(\mu\text{-Cl})_2$ (**1**), mononuclear $[(\text{DMOX})\text{CuBr}_2]$ (**2**) and pybox Cu complexes $[(\text{Dm-Pybox})\text{CuBr}_2]$ (**3**) were obtained by the reactions of CuX_2 (X = Cl, Br) with DMOX and Dm-Pybox in MeOH/ CH_2Cl_2 solvents at room temperature, respectively. All Cu complexes were characterized by IR and elemental analysis, which are stable toward to air and moisture in the solid state. The complexes are moderately soluble in most of solvent such as CH_2Cl_2 , MeOH, MeCN, DMSO and DMF. Crystals of Cu complexes **1**, **2** and **3** suitable for X-ray crystallographic diffraction were obtained by slow diffusion of diethyl ether into a concentrated solution of the complexes in dichloromethane solution. The

crystallographic data for complexes **1**, **2** and **3** are summarized in Table 1, and selected bond lengths and angles are shown in Table S1.

In complexes **1** and **2**, the DMOX acts as a chelating ligand and coordinates the Cu(II) centers through the nitrogen atoms of oxazoline. As shown in Fig. 1, the crystal structure of **1** consists of binuclear units, connected by Cl anion, and each Cu atom is coordinated by two N atoms of DMOX ligand and three Cl atoms. The Cu(II) metal is five-coordinate and exhibits distorted trigonal-bipyramidal geometry, with N₁Cu₁Cl₂ as the principal axis (N(1)-Cu(1)-Cl(2) bond angle is 171.46(5)°, which is different from the distorted square-pyramidal geometry of [$\{\text{Cu}(\text{DPS})\text{Cl}\}_2(\mu\text{-Cl})_2$] (DPS = Di(2-pyridyl)sulfide).¹⁰ The equatorial Cu-Cl bonds (2.2299(6) Å and 2.2660(5) Å) are shorter than the axial (2.6241(6) Å), and stronger than those of in complex [$\{\text{Cu}(\text{bipy})\text{Cl}\}_2(\mu\text{-Cl})_2$] (2.291(3) Å, 2.259(3) Å and 2.267(3) Å).¹¹ As shown in Fig. 2, the copper atom is located in N₂Br₂ distorted tetrahedral arrangement because of the restricted bite angle of DMOX, in which DMOX adopts a normal chelating coordination mode using its two sp² N atoms from the oxazoline fragments. The bond length of N-Cu are 2.031(7) Å and 2.116(6) Å, respectively, which is slightly longer than those observed in the [Cu((S,S)-*tert*-Bu-box)(OH₂)₂](OTf)₂ (1.921(3) Å and 1.955(3) Å) due to the bulky substituent on oxazoline group.¹² The average bond length of Cu-Br (2.3732 Å) is shorter than complex [Cu(Bipy) Br₂] (2.792 Å).¹³ The X-ray structure of **3** show four asymmetric units crystallized in the monoclinic space group *P*2₁/*n* (Fig. 3). As expected, pyridine-based pincer ligand is coordinated to copper in a tridentate fashion by the pyridyl nitrogen and two oxazoline nitrogen atoms. The coordination sphere around the Cu(II) atom is best described as midway between trigonal bipyramidal and square pyramidal in structure.¹⁴ The Cu-N distances (2.001(2), 2.102(2) and 2.071(2) Å) in **3**, which are compatible with a typical single bond length between the copper center and the nitrogen atom reported in the previous literature,¹⁵ and can be compared with others Cu complexes containing the 3N ligand set.¹⁶




Fig. 1 Molecular structure of **1** with thermal ellipsoids drawn at the 30% level, all hydrogen atoms are omitted for clarity.




Fig. 2 Molecular structure of **2** with thermal ellipsoids drawn at the 30% level, all hydrogen atoms are omitted for clarity.




Fig. 3 Molecular structure of **3** with thermal ellipsoids drawn at the 30% level, all hydrogen atoms are omitted for clarity.

In order to establish oxazoline and Pybox ligand's electronic effect on Cu early on, the reaction of propiophenone and morpholine was carried out in 10 mol % CuBr₂ and screened against a library of ligands L1-L11 (Table 2). Low yields of 2-morpholino-1-phenylpropan-1-one were observed using bicarboxylic acid and bidentate nitrogen as the ligands (Table 2, L1-L7). Little difference was observed on changing pyridine-2-carboxylic acid (L1) to 2,2'-bipyridyl (L3). However to our delight, 51% yields of desired product were observed using DMOX as the ligand (Table 2, L6). A series of tridentate pincer ligands have been screened on the model reaction (Table 2, L8-L11). The best yield amongst all is obtained with the Dm-Pybox (L9) (59%) as ligand. A control experiment without ligand, 48% yields of product were obtained.

After ligand screening, we chose Cu complex **3** as the catalyst to test the influence of solvents on reaction yield (Table 3, entries 1-9). To our pleasant surprise, DMSO drastically improved the yield to 95%. However, lower yield was obtained with lower catalyst loading 5 mol% **3** and required longer

Table 1 Crystallographic Data and Structure Refinement Parameters for Complexes **1**, **2**, **3** and **3a**


	1	2	3	3a
Empirical formula	C ₂₀ H ₃₂ Cl ₄ Cu ₂ N ₄ O ₄	C ₁₀ H ₁₆ Br ₂ CuN ₂ O ₂	C ₁₅ H ₁₉ Br ₂ CuN ₃ O ₂	C ₁₄ H ₁₉ NO ₂
Formula weight	661.38	419.61	496.69	233.30
Crystal syst., Space group	Orthorhombic, Pbc _a	Monoclinic, P2(1)/n	Monoclinic, P2(1)/n	Monoclinic, P2(1)/n
a (Å)	11.6403(9)	10.506(5)	10.5479(7)	14.4443(15)
b (Å)	14.5767(11)	12.627(6)	15.7383(11)	6.1524(6)
c (Å)	16.4463(12)	12.057(5)	11.3501(8)	14.5492(15)
α (°)	90	90	90	90
β (°)	90	115.714(5)	99.8020(10)	98.2260(10)
γ (°)	90	90	90	90
Volume (Å ³), Z	2790.6(4), 4	1441.1(11), 4	1856.7(2), 4	1279.6(2), 4
D _c (mg / m ³)	1.574	1.934	1.777	1.211
μ (Mo-Kα) (mm ⁻¹)	1.939	7.053	5.491	0.080
F(000)	1352	820	980	504
θ range (°)	2.48 ~ 27.69	2.15 ~ 27.57	2.23 ~ 27.32	2.83 ~ 27.43
Limiting indices	-15, 14, -19, 17, -21, 21	-12, 13, -15, 16, -15, 15	-13, 13, -20, 20, -13, 14	-18, 18, -7, 7, -18, 18
Reflections/unique[R(int)]	22830/3261[0.0299]	11871/3309[0.1099]	15784/4219 [0.0363]	10565/2904 [0.0512]
Completeness to θ (°)	27.69 (99.8%)	27.57 (98.9%)	27.41 (99.6%)	27.43 (99.5%)
Data/restraints/parameters	3261 / 0 / 158	3309 / 0 / 154	4219 / 0 / 212	2904 / 0 / 154
Goodness-of-fit on F ²	1.042	0.933	1.028	0.998
R ₁ , wR ₂ [I > 2σ(I)] ^a	0.0264, 0.0676	0.0581, 0.1252	0.0282, 0.0639	0.0483, 0.1086
R ₁ , wR ₂ (all data)	0.0354, 0.0722	0.1637, 0.1699	0.0446, 0.0702	0.1085, 0.1341
Larg. diff. peak / hole (e/Å ⁻³)	0.510/-0.301	0.156/-1.037	0.436/-0.421	0.200/-0.151

^a R₁ = Σ||F_o|-|F_c||/Σ|F_o|; wR₂ = [Σw(|F_o²|-|F_c²|)²/Σw|F_o²|]^{1/2}.


reaction time of 20 hours (Table 3, entry 7). The yield remains unchanged with 15 mol% of **3** and reaction time shorter 6 hours (Table 3, entry 8). A control experiment with copper catalyst absent failed to see any reaction (Table 3, entry 11).

With the best reaction conditions on hand, we started to expand the scope and efficiency of this methodology. A series of α-amination of carbonyl compounds were obtained in good to excellent yields (Table 4). The morpholine with electron-withdrawing and electron-donating substituents on the aromatic backbone were investigated to provide the desired products in high yields (Table 4 **3a**, **4a** and **5a**). The configuration of **3a**

was determined by X-ray crystallographic analysis (Figure 4). More specifically, the efficient conversion of electron-deficient ketones was achieved at low temperatures (Table 4 **5a**, **13a**, **19a** and **27a**). Ethyl phenylacetate readily undergo morpholine, piperidine or 1,2,3,4-tetrahydroisoquinoline incorporation in the presence of catalytic **3** to generate ethyl phenylacetate derivatives (Table 4 **7a**, **21a** and **30a**). Heteroaromatic substrate 2-butyrylthiophene were also transformed well under the standard conditions, for example, 2-morpholino-1-(thiophen-2-yl)butan-1-one (**8a**), 2-thiomorpholino-1-(thiophen-2-yl)butan-1-one (**14a**), 2-(piperidin-1-yl)-1-(thiophen-2-yl)butan-1-one

Table 2 Ligands tested in the CuBr₂-catalyzed α -Amination of propiophenone^{a,b}

^a Reaction conditions: CuBr₂ (11.2 mg, 0.05 mmol, 0.1equiv); L1-L10 (0.05 mmol, 0.1 equiv); DMF (0.5 mL); propiophenone (67 μ L, 0.5 mmol, 1.0 equiv); morpholine (130 μ L, 1.5 mmol, 3.0 equiv); 25 $^{\circ}$ C; 10 hours and under air; ^b isolated yields.


**Fig. 4** Molecular structure of **3a** with thermal ellipsoids drawn at the 30% level, all hydrogen atoms are omitted for clarity.

(**22a**) and 2-(3,4-dihydroisoquinolin-2(1H)-yl)-1-(thiophen-2-yl)butan-1-one (**28a**) were obtained from the corresponding second amine in 93%, 84%, 93% and 89% yields, respectively (Table 4).

Conclusions


















Table 4 Cu complex catalyzed α -Amination of Carbonyls














In conclusion, we have reported the synthesis of three novel Cu(II) complexes with oxazoline and Pybox ligands, respectively. All complexes have been fully characterized and molecular structures were determined by X-ray diffraction analysis. Binuclear [(DMOX)CuCl]₂(μ -Cl)₂ (**1**) and mononuclear [(DMOX)CuBr₂] (**2**) complexes containing DMOX as a chelating ligand. Moreover, [(Dm-Pybox)CuBr₂] (**3**) is efficient in catalyzing α -amination of ketones and esters through C-N coupling reaction, which readily tolerates a range of functionality on the carbonyl and amine reaction components. We believe that when aldehydes as substrates are used, it will be possible to synthesize α -amination derivatives following this general strategy, and the work is in progress.

Table 3 Optimized reaction condition screen for Cu complex catalyzed α -Amination of propiophenone^{a,b}

Entry	Cu catalyst (10 mol %)	Solvent	Yield (%) ^a
1	3	MeCN	31
2	3	MeOH	38
3	3	THF	40
4	3	DMF	59
5	3	DMSO	95
6	3	DMSO	75 ^b
7	3	DMSO	81 ^c
8	3	DMSO	96 ^d
9	1	DMSO	20
10	2	DMSO	94
11		DMSO	NR

^a Isolated yield; ^b 1 mol% catalyst, reaction time: 40 h; ^c 5 mol% catalyst, reaction time: 20 h; ^d 15 mol% catalyst, reaction time: 6 h.

**1a**, 96%**2a**, 94%**3a**, 94%**4a**, 93%**5a**, 97%^b**6a**, 69%^c**7a**, 65%^c**8a**, 93%**9a**, 90%**10a**, 89%**11a**, 82%^c**12a**, 80%^c**13a**, 74%^b**14a**, 84%**15a**, 95%**16a**, 95%

**17a**, 94%**18a**, 92%**19a**, 97%^b**20a**, 87%^c**21a**, 84%^c**22a**, 93%**23a**, 94%**24a**, 95%**25a**, 93%**26a**, 92%**27a**, 87%^b**28a**, 89%**29a**, 86%^c**30a**, 81%^c

^a Isolated yield; ^b reaction was carry out at 10 °C; ^c reaction was carry out at 50 °C

Experimental Section

General: Commercial reagents were analytical grade and used as received from Aladdin and Alfa aesar. All reactions were performed in oven-dried or flame-dried glassware, and were monitored by TLC using 0.25 mm silica gel plates with UV indicator (60F-254). All solvent were purified and degassed by standard procedures. The starting materials 4,5-Dihydro-2-(4,5-

dihydro-4,4-dimethyloxazol-2-yl)-4,4-dimethyloxazole (L6 DMOX);¹⁷ 2,6-bis[4',4'-dimethyloxazolin-2'-yl]pyridine (Dm-Pybox L9)¹⁸ 2,6-bis(4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine (L10)¹⁸ and 2,6-bis(4-phenyl-4,5-dihydrooxazol-2-yl)pyridine (L11)¹⁸ were synthesized according to the procedures described in the literature. ¹H and ¹³C NMR were recorded on a 300 MHz or 500 MHz NMR spectrometer at room temperature. Chemical shifts (δ) are given in ppm relative

to CDCl_3 (7.26 ppm for ^1H and 77 ppm for ^{13}C) or internal TMS. High-resolution mass spectra (HRMS) were obtained using APCI-TOF in positive mode. IR spectra were recorded on a Nicolet AVATAR-360IR spectrometer. Element analyses were performed on an Elementar III vario EI Analyzer.

Preparation of Binuclear Complex $[(\text{DMOX})\text{CuCl}_2(\mu\text{-Cl})_2]$ (**1**)

A 50 mL round-bottomed flask was placed with DMOX (39 mg, 0.2 mmol), $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ (34 mg, 0.2 mmol), 10 mL MeOH and 10 mL CH_2Cl_2 as solvent. The mixture was stirred at room temperature for 5 h and then the solvent was removed with the rotary evaporator; the resulting solid was washed with Et_2O . The product was dried under vacuum to give corresponding green complex **1** (64 mg, 96%). Anal. Calcd. for $\text{C}_{20}\text{H}_{32}\text{Cl}_4\text{Cu}_2\text{N}_4\text{O}_4$: C 36.32, H 4.88, N 8.47 Found: C 36.25, H 4.65, N 8.57. IR (KBr cm^{-1}): 2966(m), 2920(w), 1650(vs), 1487(s), 1458(m), 1401(w), 1365(s), 1332(m), 1274(m), 1217(w), 1160(w), 1045(s), 996(w), 923(s), 824(m), 627(w), 505(s).

Preparation of mononuclear $[(\text{DMOX})\text{CuBr}_2]$ (**2**)

A 50 mL round-bottomed flask was placed with DMOX (39 mg, 0.2 mmol), CuBr_2 (45 mg, 0.2 mmol), 10 mL MeOH and 10 mL CH_2Cl_2 as solvent. The mixture was stirred at room temperature for 5 h and then the solvent was removed with the rotary evaporator; the resulting solid was washed with Et_2O . The product was dried under vacuum to give corresponding dark purple complex **2** (78 mg, 93%). Anal. Calcd. for $\text{C}_{10}\text{H}_{16}\text{Br}_2\text{CuN}_2\text{O}_2$: C 28.62, H 3.84, N 6.68 Found: C 28.59, H 3.64, N 6.47. IR (KBr cm^{-1}): 2967(m), 2923(w), 1656(s), 1503(s), 1465(s), 1363(s), 1331(s), 1261(m), 1204(m), 1159(w), 999(m), 930(s), 828(w), 618(m).

Preparation of pybox copper complex $[(\text{Dm-Pybox})\text{CuBr}_2]$ (**3**)

A 50 mL round-bottomed flask was placed with (Dm-pybox) (55 mg, 0.2 mmol), CuBr_2 (45 mg, 0.2 mmol), 10 mL MeOH and 10 mL CH_2Cl_2 as solvent. The mixture was stirred at room temperature for 5 h and then the solvent was removed with the rotary evaporator; the resulting solid was washed with Et_2O . The product was dried under vacuum to give corresponding dark green complex $[(\text{Dm-Pybox})\text{CuBr}_2]$ (**3**) (94 mg, 95%). Anal. Calcd. for $\text{C}_{15}\text{H}_{19}\text{Br}_2\text{CuN}_3\text{O}_2$: C 36.27, H 3.86, N 8.46 Found: C 36.18, H 3.65, N 8.50. IR (KBr cm^{-1}): 3025(m), 2968(w), 2929(w), 1643(m), 1624(s), 1573(s), 1497(m), 1452(w), 1401(s), 1381(m), 1338(m), 1293(m), 1197(s), 1097(m), 1025(m), 980(m), 943(s), 841(m), 764(w), 669(s).

General procedure for the synthesis α -amination of ketones and esters

3 (25 mg, 0.05 mmol, 0.1 equiv) was dissolved in DMSO (0.1–0.5 mL), then appropriate ketone (0.5 mmol, 1.0 equiv) was added. This mixture was stirred for 10 minutes at room temperature before the addition of second amine (1.5 mmol, 3.0 equiv). The reaction was stirred for 10 hours, after which the crude reaction mixture was loaded directly onto a column of

silica gel and purified by column chromatography to give the desired products.

2-Morpholino-1-phenylpropan-1-one (**1a**).⁹

Yellow liquid, 96% yield (105 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.02 (d, $J = 7.20$ Hz, 2H), 7.49 (t, $J = 7.20$ Hz, 1H), 7.40 (t, $J = 7.20$ Hz, 2H), 4.00 (q, $J = 6.75$ Hz, 1H), 3.63 (m, 4H), 2.52 (m, 4H), 1.22 (d, $J = 6.75$ Hz, 3H).

2-Morpholino-1-phenylbutan-1-one (**2a**).¹⁹

Yellow liquid, 94% yield (110 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.03 (d, $J = 7.20$ Hz, 2H), 7.54 (t, $J = 7.20$ Hz, 1H), 7.43 (t, $J = 7.20$ Hz, 2H), 3.99 (q, $J = 4.80$ Hz, 1H), 3.63 (m, 4H), 2.59 (m, 4H), 1.88 (m, 1H), 1.74 (m, 1H), 0.84 (t, $J = 7.53$ Hz, 3H).

1-(1-p-tolyl)-2-morpholinopropan-1-one (**3a**).

Yellow liquid, 94% yield (110 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.93 (d, $J = 7.90$ Hz, 2H), 7.19 (d, $J = 7.89$ Hz, 2H), 3.99 (m, 1H), 3.63 (m, 4H), 2.54 (m, 4H), 2.35 (s, 3H), 1.22 (d, $J = 6.9$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 200.19, 144.24, 133.86, 129.44, 129.20, 67.40, 64.92, 50.43, 21.96, 12.36. HRMS (APCI) Calcd. for $\text{C}_{14}\text{H}_{19}\text{NO}_2$ $[\text{M} + \text{H}]^+$ 234.1489, found 234.1483.

1-(4-Methoxyphenyl)-2-morpholinopropan-1-one (**4a**).⁹

Yellow liquid, 93% yield (116 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.06 (d, $J = 8.70$ Hz, 2H), 6.99 (d, $J = 8.70$ Hz, 2H), 3.96 (q, $J = 6.90$ Hz, 1H), 3.82 (s, 3H), 3.64 (m, 4H), 2.54 (m, 4H), 1.24 (d, $J = 6.90$ Hz, 3H).

1-(4-chlorophenyl)-2-morpholinopropan-1-one (**5a**).

Yellow liquid, 97% yield (123 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.06 (d, $J = 8.10$ Hz, 2H), 7.41 (d, $J = 8.10$ Hz, 2H), 4.00 (q, $J = 6.90$ Hz, 1H), 3.66 (m, 4H), 2.57 (m, 4H), 1.27 (d, $J = 6.90$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 199.29, 139.79, 134.60, 130.70, 129.06, 67.39, 65.36, 50.23, 11.49. HRMS (APCI) Calcd. for $\text{C}_{13}\text{H}_{16}\text{ClNO}_2$ $[\text{M} + \text{H}]^+$ 254.0942, found 254.0940.

Methyl 2-morpholino-2-phenylacetate (**6a**).⁹

Pale yellow liquid, 69% yield (81 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.36 (m, 2H), 7.24 (m, 3H), 3.90 (s, 1H), 3.64 (m, 4H), 3.60 (s, 3H), 2.37 (m, 4H).

Ethyl 2-morpholino-2-phenylacetate (**7a**).

Pale yellow liquid, 65% yield (81 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.37 (m, 2H), 7.24 (m, 3H), 4.07 (m, 2H), 3.88 (s, 1H), 3.65 (m, 4H), 2.38 (m, 4H), 1.12 (t, $J = 7.05$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 171.52, 135.75, 129.18, 128.91, 128.76, 74.83, 67.12, 61.28, 51.91, 14.41. HRMS (APCI) Calcd. for $\text{C}_{14}\text{H}_{19}\text{NO}_3$ $[\text{M} + \text{H}]^+$ 250.1438, found 250.1440.

2-Morpholino-1-(thiophen-2-yl)butan-1-one (**8a**).

Yellow liquid, 93% yield (111 mg). ^1H NMR (500 MHz, CDCl_3) δ 7.89 (d, $J = 3.50$ Hz, 1H), 7.57 (d, $J = 3.50$ Hz, 1H), 7.07 (t, $J = 3.5$ Hz, 1H), 3.64 (m, 4H), 3.51 (m, 1H), 2.61 (m, 2H), 2.54 (m, 2H), 1.75 (m, 2H), 0.94 (t, $J = 4.25$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 193.30, 142.76, 133.97, 132.85, 127.74, 73.04, 67.03, 50.59, 20.48, 10.90. HRMS (APCI) Calcd. for $\text{C}_{12}\text{H}_{17}\text{NO}_2\text{S}$ $[\text{M} + \text{H}]^+$ 240.1053, found 240.1051.

1-Phenyl-2-thiomorpholinopropan-1-one (**9a**).⁹

Yellow liquid, 90% yield (106 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.97 (d, $J = 7.20$ Hz, 2H), 7.47 (t, $J = 7.20$ Hz, 1H),

7.37 (t, $J = 7.20$ Hz, 2H), 4.09 (q, $J = 6.60$ Hz, 1H), 2.80 (m, 4H), 2.52 (m, 4H), 1.19 (d, $J = 6.60$ Hz, 3H).

Phenyl-2-thiomorpholinobutan-1-one (10a).

Yellow liquid, 89% yield (111 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.98 (d, $J = 7.23$ Hz, 2H), 7.54 (t, $J = 7.25$ Hz, 1H), 7.43 (t, $J = 7.24$ Hz, 2H), 3.93 (m, 1H), 2.88 (m, 4H), 2.56 (m, 4H), 1.87 (m, 1H), 1.69 (m, 1H), 0.86 (t, $J = 7.35$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 199.62, 137.66, 133.23, 128.82, 128.77, 70.94, 52.28, 28.85, 18.91, 11.64. HRMS (APCI) Calcd. for $\text{C}_{14}\text{H}_{19}\text{NOS}$ [$\text{M} + \text{H}$] $^+$ 250.1260, found 250.1261.

2-Thiomorpholino-1-p-tolylpropan-1-one (11a).

Yellow liquid, 82% yield (102 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.87 (d, $J = 8.10$ Hz, 2H), 7.15 (d, $J = 8.10$ Hz, 2H), 4.03 (m, 1H), 2.77 (m, 4H), 2.50 (m, 4H), 2.32 (s, 3H), 1.15 (d, $J = 6.90$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 199.45, 143.45, 133.45, 128.80, 128.78, 64.76, 51.37, 28.17, 21.45, 9.89. HRMS (APCI) Calcd. for $\text{C}_{14}\text{H}_{19}\text{NOS}$ [$\text{M} + \text{H}$] $^+$ 250.1260, found 250.1256.

1-(4-Methoxyphenyl)-2-thiomorpholinopropan-1-one (12a).

Yellow liquid, 80% yield (106 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.03 (d, $J = 9.00$ Hz, 2H), 6.89 (d, $J = 9.00$ Hz, 2H), 4.05 (q, $J = 6.60$ Hz, 1H), 3.84 (s, 3H), 2.83 (m, 4H), 2.57 (m, 4H), 1.21 (d, $J = 6.60$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 198.80, 163.54, 131.51, 129.35, 113.67, 65.23, 55.67, 51.83, 28.63, 10.39. HRMS (APCI) Calcd. for $\text{C}_{14}\text{H}_{19}\text{NO}_2\text{S}$ [$\text{M} + \text{H}$] $^+$ 266.1209, found 266.1213.

1-(4-Chlorophenyl)-2-thiomorpholinopropan-1-one (13a).

Yellow liquid, 74% yield (99 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.99 (d, $J = 8.40$ Hz, 2H), 7.39 (d, $J = 8.40$ Hz, 2H), 4.05 (q, $J = 6.90$ Hz, 1H), 2.81 (m, 4H), 2.58 (m, 4H), 1.22 (d, $J = 6.90$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 199.15, 139.58, 134.72, 130.81, 128.94, 65.78, 51.83, 28.68, 9.77. HRMS (APCI) Calcd. for $\text{C}_{13}\text{H}_{16}\text{ClNOS}$ [$\text{M} + \text{H}$] $^+$ 270.0714, found 270.0712.

2-Thiomorpholino-1-(thiophen-2-yl)butan-1-one (14a).

Yellow liquid, 84% yield (107 mg). ^1H NMR (500 MHz, CDCl_3) δ 7.83 (d, $J = 4.00$ Hz, 1H), 7.58 (d, $J = 4.00$ Hz, 1H), 7.08 (t, $J = 4.00$ Hz, 1H), 3.61 (m, 1H), 2.89 (m, 4H), 2.62 (m, 4H), 1.83 (m, 1H), 1.69 (m, 1H), 0.88 (t, $J = 5.00$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 192.09, 142.19, 133.01, 132.08, 126.93, 72.67, 51.51, 27.54, 18.45, 10.77. HRMS (APCI) Calcd. for $\text{C}_{12}\text{H}_{17}\text{NOS}_2$ [$\text{M} + \text{H}$] $^+$ 256.0824, found 256.0823.

1-Phenyl-2-(piperidin-1-yl)propan-1-one (15a).⁹

Yellow liquid, 95% yield (103 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.09 (m, 2H), 7.51 (m, 1H), 7.43 (m, 2H), 4.13 (q, $J = 6.90$ Hz, 1H), 2.56 (m, 4H), 1.54 (m, 4H), 1.40 (m, 2H), 1.26 (d, $J = 6.90$ Hz, 3H).

1-Phenyl-2-(piperidin-1-yl)butan-1-one (16a)

Yellow liquid, 95% yield (110 mg). ^1H NMR (500 MHz, CDCl_3) δ 8.05 (d, $J = 7.00$ Hz, 2H), 7.50 (d, $J = 7.00$ Hz, 1H), 7.42 (m, $J = 7.00$ Hz, 2H), 3.89 (q, $J = 7.50$ Hz, 1H), 2.57 (m, 2H), 2.49 (m, 2H), 1.87 (m, 1H), 1.70 (m, 1H), 1.49 (m, 4H), 1.36 (m, 2H), 0.83 (t, $J = 7.50$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 200.41, 137.87, 132.78, 128.61, 128.43, 70.58, 51.03, 26.52, 24.57, 19.49, 11.29. HRMS (APCI) Calcd. for $\text{C}_{15}\text{H}_{21}\text{NO}$ [$\text{M} + \text{H}$] $^+$ 232.1696, found 232.1696.

2-(Piperidin-1-yl)-1-p-tolylpropan-1-one (17a).

Yellow liquid, 94% yield (109 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.93 (d, $J = 8.10$ Hz, 2H), 7.16 (d, $J = 8.10$ Hz, 2H), 4.06 (q, $J = 6.90$ Hz, 1H), 2.49 (m, 4H), 2.32 (s, 3H), 1.49 (m, 4H), 1.34 (m, 2H), 1.20 (d, $J = 6.90$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 200.48, 143.75, 133.88, 129.08, 129.05, 64.82, 50.80, 26.16, 24.35, 21.72, 11.84, 11.79. HRMS (APCI) Calcd. for $\text{C}_{15}\text{H}_{21}\text{NO}$ [$\text{M} + \text{H}$] $^+$ 232.1696, found 232.1696.

1-(4-Methoxyphenyl)-2-(piperidin-1-yl)propan-1-one (18a).

Yellow liquid, 92% yield (114 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.12 (d, $J = 8.70$ Hz, 2H), 6.90 (d, $J = 8.70$ Hz, 2H), 4.00 (q, $J = 6.90$ Hz, 1H), 3.85 (s, 3H), 2.52 (m, 4H), 1.51 (m, 4H), 1.41 (m, 2H), 1.24 (d, $J = 6.90$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 199.98, 163.59, 131.62, 129.82, 113.74, 65.50, 55.76, 51.18, 26.67, 24.78, 11.94. HRMS (APCI) Calcd. for $\text{C}_{15}\text{H}_{21}\text{NO}_2$ [$\text{M} + \text{H}$] $^+$ 248.1645, found 248.1647.

1-(4-Chlorophenyl)-2-(piperidin-1-yl)propan-1-one (19a).

Yellow liquid, 97% yield (122 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.08 (d, $J = 8.40$ Hz, 2H), 7.39 (d, $J = 8.40$ Hz, 2H), 4.01 (q, $J = 6.90$ Hz, 1H), 2.51 (m, 4H), 1.51 (m, 4H), 1.39 (m, 2H), 1.23 (d, $J = 6.90$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 200.04, 139.42, 134.98, 130.88, 128.86, 65.85, 50.95, 26.58, 24.63, 10.82. HRMS (APCI) Calcd. for $\text{C}_{14}\text{H}_{18}\text{ClNO}$ [$\text{M} + \text{H}$] $^+$ 252.1150, found 252.1150.

Methyl 2-phenyl-2-(piperidin-1-yl)acetate (20a).²⁰

Yellow liquid, 87% yield (101 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.36 (m, 2H), 7.23 (m, 3H), 3.90 (s, 1H), 3.59 (s, 3H), 2.29 (m, 4H), 1.51 (m, 4H), 1.35 (m, 2H).

Ethyl 2-(piperidin-1-yl)-2-phenylacetate (21a).

Yellow liquid, 84% yield (104 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.36 (m, 2H), 7.23 (m, 3H), 4.06 (m, 2H), 3.87 (s, 1H), 2.31 (m, 4H), 1.50 (m, 4H), 1.35 (m, 2H), 1.11 (t, $J = 7.20$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 172.06, 136.65, 129.08, 128.65, 128.34, 75.23, 60.94, 52.62, 26.06, 24.64, 14.39. HRMS (APCI) Calcd. for $\text{C}_{15}\text{H}_{21}\text{NO}_2$ [$\text{M} + \text{H}$] $^+$ 248.1645, found 248.1643.

2-(Piperidin-1-yl)-1-(thiophen-2-yl)butan-1-one (22a).

Yellow liquid, 93% yield (110 mg). ^1H NMR (500 MHz, CDCl_3) δ 7.90 (d, $J = 4.00$ Hz, 1H), 7.56 (d, $J = 4.00$ Hz, 1H), 7.09 (t, $J = 4.00$ Hz, 1H), 3.53 (m, 1H), 2.59 (m, 2H), 2.50 (m, 2H), 1.82 (m, 1H), 1.74 (m, 1H), 1.55 (m, 4H), 1.39 (m, 2H), 0.86 (t, $J = 7.50$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 194.49, 143.32, 133.97, 133.08, 127.82, 73.85, 51.66, 26.52, 24.79, 20.54, 11.71. HRMS (APCI) Calcd. for $\text{C}_{13}\text{H}_{19}\text{NOS}$ [$\text{M} + \text{H}$] $^+$ 238.1260, found 238.1257.

2-(3,4-Dihydroisoquinolin-2(1H)-yl)-1-phenylpropan-1-one (23a).⁹

Yellow liquid, 94% yield (125 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.06 (m, 2H), 7.46 (m, 1H), 7.35 (m, 2H), 6.99 (m, 4H), 4.24 (q, $J = 6.90$ Hz, 1H), 3.81 (d, $J = 15.0$ Hz, 1H), 3.76 (d, $J = 15.0$ Hz, 1H), 2.77 (m, 4H), 1.31 (d, $J = 6.90$ Hz, 3H).

2-(3,4-Dihydroisoquinolin-2(1H)-yl)-1-phenylbutan-1-one (24a).

Yellow liquid, 95% yield (133 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.00 (m, 2H), 7.43 (m, 1H), 7.33 (m, 2H), 6.96 (m, 4H), 4.06 (q, $J = 4.80$ Hz, 1H), 3.80 (d, $J = 15.0$ Hz, 1H), 3.72

(d, $J = 15.0$ Hz, 1H), 2.80 (m, 2H), 2.72 (m, 2H), 1.92 (m, 1H), 1.75 (m, 1H), 0.82 (d, $J = 7.20$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 200.59, 137.84, 135.45, 135.00, 133.45, 129.19, 129.07, 128.99, 126.97, 126.44, 125.97, 70.12, 52.76, 47.70, 30.27, 19.89, 11.68. HRMS (APCI) Calcd. for $\text{C}_{19}\text{H}_{21}\text{NO}$ [$\text{M} + \text{H}$] $^+$ 280.1696, found 280.1695.

2-(3,4-Dihydroisoquinolin-2(1H)-yl)-1-p-tolylpropan-1-one (25a).

Yellow liquid, 93% yield (130 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.95 (m, 2H), 7.13 (m, 2H), 6.97 (m, 4H), 4.19 (q, $J = 6.90$ Hz, 1H), 3.80 (d, $J = 14.7$ Hz, 1H), 3.70 (d, $J = 14.7$ Hz, 1H), 2.75 (m, 4H), 2.29 (s, 3H), 1.28 (d, $J = 6.90$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 200.57, 144.09, 135.16, 134.78, 133.99, 129.42, 129.35, 126.87, 126.29, 125.84, 64.39, 52.38, 47.51, 29.91, 21.97, 11.98. HRMS (APCI) Calcd. for $\text{C}_{19}\text{H}_{21}\text{NO}$ [$\text{M} + \text{H}$] $^+$ 280.1696, found 280.1696.

2-(3,4-Dihydroisoquinolin-2(1H)-yl)-1-(4-ethoxyphenyl)propan-1-one (26a).

Yellow liquid, 92% yield (136 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.08 (m, 2H), 6.98 (m, 4H), 6.90 (m, 2H), 4.15 (q, $J = 6.90$ Hz, 1H), 3.80 (d, $J = 14.7$ Hz, 1H), 3.79 (s, 3H), 3.75 (m, 2H), 2.76 (m, 4H), 1.28 (d, $J = 6.90$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 199.46, 163.65, 135.16, 134.76, 131.61, 129.37, 128.97, 126.86, 126.27, 125.82, 113.81, 64.55, 55.67, 52.39, 47.52, 29.90, 11.99. HRMS (APCI) Calcd. for $\text{C}_{19}\text{H}_{21}\text{NO}_2$ [$\text{M} + \text{H}$] $^+$ 296.1645, found 296.1643.

1-(4-Chlorophenyl)-2-(3,4-dihydroisoquinolin-2(1H)-yl)propan-1-one (27a).

Yellow liquid, 87% yield (130 mg). ^1H NMR (300 MHz, CDCl_3) δ 8.02 (m, 2H), 7.27 (m, 2H), 6.97 (m, 4H), 4.14 (q, $J = 6.90$ Hz, 1H), 3.77 (d, $J = 14.7$ Hz, 1H), 3.69 (d, $J = 14.7$ Hz, 1H), 2.72 (m, 4H), 1.28 (d, $J = 6.90$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 199.61, 139.61, 134.91, 134.64, 130.85, 129.05, 128.98, 126.87, 126.43, 125.94, 64.94, 52.23, 47.38, 29.89, 11.02. HRMS (APCI) Calcd. for $\text{C}_{18}\text{H}_{16}\text{ClNO}$ [$\text{M} + \text{H}$] $^+$ 300.1150, found 300.1144.

2-(3,4-Dihydroisoquinolin-2(1H)-yl)-1-(thiophen-2-yl)butan-1-one (28a).

Yellow liquid, 89% yield (127 mg). ^1H NMR (500 MHz, CDCl_3) δ 7.98 (m, 1H), 7.57 (m, 1H), 7.11 (m, 4H), 7.01 (m, 1H), 3.96 (m, 1H), 3.83 (m, 2H), 2.90 (m, 4H), 1.98 (m, 1H), 1.92 (m, 1H), 0.96 (d, $J = 7.50$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 194.03, 143.28, 135.02, 134.73, 134.32, 133.30, 129.03, 128.08, 126.86, 126.39, 125.90, 72.71, 52.84, 48.03, 29.77, 20.93, 11.58. HRMS (APCI) Calcd. for $\text{C}_{17}\text{H}_{19}\text{NOS}$ [$\text{M} + \text{H}$] $^+$ 286.1260, found 286.1263.

Methyl 2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-phenylacetate (29a).

Yellow liquid, 86% yield (121 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.51 (m, 2H), 7.37 (m, 3H), 7.10 (m, 3H), 6.95 (m, 1H), 4.25 (s, 1H), 3.74 (s, 3H), 3.70 (m, 2H), 2.82 (m, 4H). ^{13}C NMR (125 MHz, CDCl_3) δ 172.45, 136.36, 134.58, 129.16, 129.05, 128.86, 127.04, 126.57, 126.06, 73.91, 54.26, 52.51, 48.72, 29.20. HRMS (APCI) Calcd. for $\text{C}_{18}\text{H}_{19}\text{NO}_2$ [$\text{M} + \text{H}$] $^+$ 282.1489, found 282.1487.

Ethyl 2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-phenylacetate (30a).

Yellow liquid, 81% yield (119 mg). ^1H NMR (300 MHz, CDCl_3) δ 7.51 (m, 2H), 7.37 (m, 3H), 7.10 (m, 3H), 6.94 (m, 1H), 4.19 (m, 2H), 4.18 (s, 1H), 3.70 (m, 2H), 2.80 (m, 4H), 1.24 (t, $J = 7.08$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 171.79, 136.33, 134.56, 134.48, 129.00, 128.89, 128.82, 128.59, 126.88, 126.38, 125.82, 73.77, 61.18, 54.01, 48.55, 29.06, 14.37. HRMS (APCI) Calcd. for $\text{C}_{19}\text{H}_{21}\text{NO}_2$ [$\text{M} + \text{H}$] $^+$ 296.1645, found 296.1647.

X-ray crystallography for 1, 2, 3 and 3a:

Diffraction data of **1**, **2**, **3** and **3a** were collected on a Bruker Smart CCD diffractometer with graphite-monochromated $\text{MoK}\alpha$ radiation ($\lambda = 0.71073$ Å). All the data were collected at room temperature and the structures were solved by direct methods and subsequently refined on F^2 by using full-matrix least-squares techniques (SHELXL)²¹, and SADABS absorption corrections²² applied to the data.

Acknowledgment

This work was supported by the National Nature Science Foundation of China (21102004), and the Natural Science Foundation of the Anhui Higher Education Institutions of China (KJ2011A146), and the Project-sponsored by SRF for ROCS, SEM. K.-W. Huang acknowledges financial support from KAUST. We also thank Dr. Richmond Lee for English polishing.

Notes and references

^a College of Chemistry and Materials Science, Center for Nano Science and Technology, The Key Laboratory of Functional Molecular Solids, Ministry of Education, Anhui Laboratory of Molecular-Based Materials, Anhui Normal University, Wuhu, 241000, China
wgijasy@mail.ahnu.edu.cn (W. -G. Jia)
shengeh@mail.ahnu.edu.cn (E. -H. Sheng)

^b Division of Chemical and Life Sciences and Engineering and KAUST Catalysis Center, King Abdullah University of Science and Technology (KAUST), Thuwal, 23955-6900, Saudi Arabia.
hkw@kaust.edu.sa (K. -W. Huang)

† Electronic Supplementary Information (ESI) available: Additional copies of NMR spectra and CCDC 973034, 981179, 973033 and 978999 crystallographic information files (CIFs) for complex **1**, **2**, **3** and **3a** are available, See DOI 10.1039/

- (a) J. S. Johnson and D. A. Evans, *Acc. Chem. Res.*, 2000, **33**, 325-335;
(b) D. Rechavi and M. Lemaire, *Chem. Rev.*, 2002, **102**, 3467-3493.; (c) G. Desimoni, G. Faita and K. A. Jørgensen, *Chem. Rev.*, 2011, **111**, PR284-PR437.
- (a) H. Nishiyama and J. Ito, *Chem. Commun.*, 2010, **46**, 203-212; (b) G. Desimoni, G. Faita and P. Quadrelli, *Chem. Rev.*, 2003, **103**, 3119-3154; (c) H. A. McManus and P. J. Guiry, *Chem. Rev.*, 2004, **104**, 4151-4202; (d) G. C. Hargaden and P. J. Guiry, *Chem. Rev.*, 2009, **109**, 2505-2550; (e) H. Nishiyama, *Chem. Soc. Rev.*, 2007, **36**, 1133-1141.
- (a) R. Rasappan, D. Laventine and O. Reiser, *Coord. Chem. Rev.*, 2008, **252**, 702-714; (b) H.-Q. Do, E. R. R. Chandrashekar and G. C. Fu, *J. Am. Chem. Soc.*, 2013, **135**, 16288-16291; (c) O. Hoarau, H. Ait-Haddou, J.-C. Daran, D. Cramailère and G. G. A. Balavoine,

- Organometallics*, 1999, **18**, 4718-4723; (d) Z. Sun, S. Yu, Z. Ding and D. Ma, *J. Am. Chem. Soc.*, 2007, **129**, 9300-9301. (e) Q.-H. Deng, H. Wadepohl and L. H. Gade, *J. Am. Chem. Soc.*, 2012, **134**, 10769-10772; (f) C. P. Owens, A. Varela-Alvarez, V. Boyarskikh, D. G. Musaev, H. M. L. Davies and S. B. Blakey, *Chem. Sci.*, 2013, **4**, 2590-2596; (g) J.-F. Zhao, B.-H. Tan and T.-P. Loh, *Chem. Sci.*, 2011, **2**, 349-352; (h) H. Nguyen and M. R. Gagné, *ACS Catal.*, 2014, **4**, 855-859; (i) S. Rout, S. K. Ray and V. K. Singh, *Org. Biomol. Chem.*, 2013, **11**, 4537-4545; (j) M. Irmak and M. M. K. Boysen, *Adv. Synth. Catal.*, 2008, **350**, 403-405.
- 4 (a) A. Sakakura and K. Ishihara, *Chem. Soc. Rev.*, 2011, **40**, 163-172; (b) G. Evano, N. Blanchard and M. Toumi, *Chem. Rev.*, 2008, **108**, 3054-3131; (c) S. V. Ley and A. W. Thomas, *Angew. Chem. Int. Ed.*, 2003, **42**, 5400-5449; (d) A. E. Wendlandt, A. M. Suess and S. S. Stahl, *Angew. Chem. Int. Ed.*, 2011, **50**, 11062-11087; (e) S.-L. Huang, Y.-J. Lin, T. S. A. Hor and G.-X. Jin, *J. Am. Chem. Soc.*, 2013, **135**, 8125-8128; (f) H. Li, Y.-F. Han, Y.-J. Lin, Z.-W. Guo and G.-X. Jin, *J. Am. Chem. Soc.*, 2014, **136**, 2982-2985; (g) Z. Q. Weng, W. M. He, C. H. Chen, R. Lee, D. Tan, Z. P. Lai, D. D. Kong, Y. F. Yuan, K. W. Huang, *Angew. Chem. Int. Ed.*, 2013, **52**, 1548-1552.
- 5 (a) M. Panera, J. Diez, I. Merino, E. Rubio and M. P. Gamasa, *Eur. J. Inorg. Chem.*, 2011, 393-404; (b) M. Panera, J. Diez, I. Merino, E. Rubio and M. P. Gamasa, *Inorg. Chem.*, 2009, **48**, 11147-11160. (c) G. C. Hargaden and P. J. Guiry, *Chem. Rev.*, 2009, **109**, 2505-2550; (d) L. H. Gade and S. Bellemin-Lapponnaz, *Coord. Chem. Rev.*, 2007, **251**, 718-725.
- 6 (a) C. Bouteiller, J. Becerril-Ortega, P. Marchand, O. Nicole, L. Barre, A. Buisson and C. Perrio, *Org. Biomol. Chem.*, 2010, **8**, 1111-1120; (b) E. M. Nurminen, M. Pihlavisto, L. s. Lázár, U. Pentikäinen, F. Fülöp and O. T. Pentikäinen, *J. Med. Chem.*, 2011, **54**, 2143-2154; (c) P. C. Meltzer, D. Butler, J. R. Deschamps and B. K. Madras, *J. Med. Chem.*, 2006, **49**, 1420-1432; (d) R. Kolanos, E. Solis, F. Sakloth, L. J. De Felice and R. A. Glennon, *ACS Chem. Neurosci.*, 2013, **4**, 1524-1529.
- 7 (a) J.-S. Tian and T.-P. Loh, *Angew. Chem. Int. Ed.*, 2010, **49**, 8417-8420; (b) J.-S. Tian, K. W. J. Ng, J.-R. Wong, and T.-P. Loh, *Angew. Chem. Int. Ed.*, 2012, **51**, 9105-9109; (c) J.-S. Tian and T.-P. Loh, *Chem. Commun.*, 2011, **47**, 5458-5460.
- 8 N. Matsuda, K. Hirano, T. Satoh and M. Miura, *Angew. Chem. Int. Ed.*, 2012, **51**, 11827-11831.
- 9 R. W. Evans, J. R. Zbieg, S. Zhu, W. Li and D. W. MacMillan, *J. Am. Chem. Soc.*, 2013, **135**, 16074-16077.
- 10 W. M. Teles, M. V. Marinho, M. I. Yoshida, N. L. Speziali, K. Krambrock, C. B. Pinheiro, N. M. Pinhal, A. A. Leitao and F. C. Machado, *Inorg. Chim. Acta*, 2006, **359**, 4613-4618.
- 11 M. Hernandez-Molina, J. Gonzalez-Platas, C. Ruiz-Perez, F. Lloret and M. Julve, *Inorg. Chim. Acta*, 1999, **284**, 258-265.
- 12 D. A. Evans, S. J. Miller, T. Lectka and P. von Matt, *J. Am. Chem. Soc.*, 1999, **121**, 7559-7573.
- 13 M. T. Garland, D. Grandjean, E. Spodine, A. M. Atria and J. Manzur, *Acta Crystallogr., Sect. C: Cryst. Struct. Commun.*, 1988, **44**, 1209-1212.
- 14 A. W. Addison, T. N. Rao, J. Reedijk, J. van Rijn and G. C. Verschoor, *J. Chem. Soc., Dalton Trans.*, 1984, 1349-1356.
- 15 D. A. Evans, S. J. Miller, T. Lectka and P. von Matt, *J. Am. Chem. Soc.*, 1999, **121**, 7559-7573.
- 16 (a) D. A. Evans, D. M. Barnes, J. S. Johnson, T. Lectka, P. von Matt, S. J. Miller, J. A. Murry, R. D. Norcross, E. A. Shaughnessy and K. R. Campos, *J. Am. Chem. Soc.*, 1999, **121**, 7582-7594; (b) Q.-H. Deng, H. Wadepohl and L. H. Gade, *J. Am. Chem. Soc.*, 2012, **134**, 2946-2949; (c) T. Arai, A. Mishiro, N. Yokoyama, K. Suzuki and H. Sato, *J. Am. Chem. Soc.*, 2010, **132**, 5338-5339.
- 17 G. Altenhoff, R. Goddard, C. W. Lehmann and F. Glorius, *J. Am. Chem. Soc.*, 2004, **126**, 15195-15201.
- 18 H. Nishiyama, M. Kondo, T. Nakamura and K. Itoh, *Organometallics*, 1991, **10**, 500-508.
- 19 M. Lamani and K. R. Prabhu, *Chem. Eur. J.*, 2012, **18**, 14638-14642.
- 20 T. Miura, M. Morimoto and M. Murakami, *Org. Lett.*, 2012, **14**, 5214-5217.
- 21 G. Sheldrick, *SHELXL-97, Program for the Refinement of Crystal Structures*, 1997.
- 22 G. Sheldrick, *SADABS v. 2.01, Bruker/Siemens area detector absorption correction program*, 1998.